RU-22930

RU-22930 is a nonsteroidal antiandrogen (NSAA) related to the NSAAs flutamide and nilutamide (RU-23908) and was developed by Roussel Uclaf but was never marketed.^[2][3] It is a selective antagonist of the androgen receptor and consequently has progonadotropic effects by increasing gonadotropin and testosterone levels via disinhibition of the hypothalamic-pituitary-gonadal axis.^[2] Unlike flutamide and nilutamide, the drug is said to be short-acting and inactive by injection, but it has been found to be active topically in animals, and hence could be useful for the treatment of androgen-dependent skin conditions.^[2][4]

RU-22930

Clinical data
Other names	5,6-Dihydro-2-methyl-4-[4-nitro-3-(trifluoromethyl)phenyl]-2H-1,2,4-oxadiazin-3-(4H)-one[1]
Drug class	Nonsteroidal antiandrogen
Identifiers
IUPAC name 2-Methyl-4-[4-nitro-3-(trifluoromethyl)phenyl]-1,2,4-oxadiazinan-3-one
CAS Number	63094-42-8 Y
PubChem CID	9948430
ChemSpider	8124041
UNII	99QTV3S3MG
CompTox Dashboard (EPA)	DTXSID501336998
Chemical and physical data
Formula	C11H10F3N3O4
Molar mass	305.213 g·mol−1
3D model (JSmol)	Interactive image
SMILES CN1OCCN(C1=O)C1=CC=C(C(=C1)C(F)(F)F)N(=O)=O
InChI InChI=1S/C11H10F3N3O4/c1-15-10(18)16(4-5-21-15)7-2-3-9(17(19)20)8(6-7)11(12,13)14/h2-3,6H,4-5H2,1H3 Key:SQAORNVRAYTOMS-UHFFFAOYSA-N

See also

• RU-58642
• RU-58841